Zafgen (ZFGN) Lifted to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Zafgen (NASDAQ:ZFGN) from a sell rating to a hold rating in a research note issued to investors on Saturday.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also recently issued reports on ZFGN. Cowen reaffirmed a hold rating on shares of Zafgen in a report on Thursday, January 17th. Leerink Swann raised shares of Zafgen from a market perform rating to an outperform rating and set a $4.52 price target for the company in a report on Thursday, February 7th. ValuEngine raised shares of Zafgen from a buy rating to a strong-buy rating in a report on Saturday, November 10th. BidaskClub cut shares of Zafgen from a buy rating to a hold rating in a report on Thursday, November 22nd. Finally, Svb Leerink raised shares of Zafgen from a market perform rating to an outperform rating in a report on Thursday, February 7th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Zafgen has a consensus rating of Buy and an average price target of $12.45.

NASDAQ:ZFGN opened at $4.47 on Friday. Zafgen has a 52 week low of $4.10 and a 52 week high of $12.35. The company has a debt-to-equity ratio of 0.16, a current ratio of 11.78 and a quick ratio of 11.78. The company has a market cap of $164.81 million, a P/E ratio of -2.35 and a beta of -0.36.

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Manhattan Co. purchased a new position in shares of Zafgen in the fourth quarter worth $27,000. Meeder Asset Management Inc. raised its holdings in shares of Zafgen by 547.1% during the fourth quarter. Meeder Asset Management Inc. now owns 9,118 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 7,709 shares during the last quarter. Voya Investment Management LLC purchased a new position in shares of Zafgen during the second quarter worth $104,000. Prudential Financial Inc. purchased a new position in shares of Zafgen during the fourth quarter worth $65,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Zafgen by 428.7% during the third quarter. Wells Fargo & Company MN now owns 14,783 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 11,987 shares during the last quarter. 81.96% of the stock is owned by institutional investors and hedge funds.

About Zafgen

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Further Reading: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Nektar Therapeutics  Shares Sold by Gotham Asset Management LLC
Nektar Therapeutics Shares Sold by Gotham Asset Management LLC
Cipher Capital LP Takes $906,000 Position in New York Times Co
Cipher Capital LP Takes $906,000 Position in New York Times Co
Cipher Capital LP Invests $821,000 in Sensata Technologies Holding PLC  Stock
Cipher Capital LP Invests $821,000 in Sensata Technologies Holding PLC Stock
Capital Financial Planning LLC Buys New Position in NEWTEK Business Services Corp
Capital Financial Planning LLC Buys New Position in NEWTEK Business Services Corp
Genuine Parts  Position Lowered by Fmr LLC
Genuine Parts Position Lowered by Fmr LLC


© 2006-2019 Ticker Report